Physician profile
Daniel J Ramirez
NPI 1053806547
$3,071.71
in general payments reported to CMS, 2019-2025
22 companies · $648 in 2025
The $648 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $186 · 2021: $74.96 · 2022: $432 · 2023: $837 · 2024: $677 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.42 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $319.51 | 2022-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.35 | 2022-2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $183.16 | 2025 | Axios |
| Janssen Scientific Affairs, LLC | $177.19 | 2019-2022 | |
| Ambu INC. | $171.94 | 2020 | |
| Genzyme Corporation | $168.40 | 2023-2025 | |
| Janssen Biotech, INC. | $160.03 | 2020-2023 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $146.00 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $121.00 | 2023-2024 | Dupixent |
| Pfizer INC. | $99.27 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.90 | 2023-2024 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $87.91 | 2024 | Rezdiffra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.70 | 2019 | |
| Gilead Sciences, INC. | $74.06 | 2024 | Epclusa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $48.18 | 2023 | Renflexis, Hadlima |
| Astrazeneca Pharmaceuticals LP | $32.53 | 2019 | |
| Ardelyx, INC. | $16.87 | 2023 | Ibsrela |
| Braintree Laboratories, INC. | $16.38 | 2023 | Sutab |
| Teva Pharmaceuticals USA, INC. | $16.06 | 2021 | |
| Lilly USA, LLC | $15.95 | 2024 | Omvoh |
| Radius Health, INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.